8-K: CalciMedica Announces Positive AKI Data from Post-Hoc Analysis of Phase 2 CARDEA Trial

CalciMedica's post-hoc analysis of the CARDEA trial shows Auxora significantly reduced mortality in COVID-19 pneumonia patients with acute kidney injury (AKI).

Summary

• CalciMedica announced data from a post-hoc analysis of the Phase 2 CARDEA trial evaluating Auxora for severe COVID-19 pneumonia.
• The analysis focused on a subset of 38 patients with Acute Kidney Injury (AKI).
• Patients treated with Auxora showed a 62.7% relative reduction in mortality at day 30, persisting through day 60, compared to placebo.
• In the placebo group, 46.7% of patients died by day 30 and day 60, compared to 17.4% in the Auxora group.
• Auxora exhibited an absolute reduction in mortality of 29.3% in the AKI subset.
• This mortality reduction in the AKI subset was greater than that observed in the entire study population (n=261), which showed a 56.3% relative reduction and a 9.9% absolute reduction in mortality at day 30.
• The company also presented data supporting CRAC channel inhibition as a potential therapeutic mechanism in AKI, including preclinical and clinical biomarker studies.

Sentiment

Score: 7

Explanation: The announcement highlights positive data from a post-hoc analysis, suggesting potential for Auxora in treating AKI. However, it's important to note that the data is from a post-hoc analysis and the company needs additional capital, which tempers the overall positive sentiment.

Positives

• Auxora shows a significant reduction in mortality in a subset of COVID-19 patients with AKI.
• The data supports the potential of CRAC channel inhibition as a therapeutic target for AKI.
• Preclinical and clinical data provide a biological rationale for Auxora's mechanism of action in AKI.
• Auxora potentially provides a therapeutic window to treat acute critical illnesses without increasing risk of infection.

Risks

• The results are based on a post-hoc analysis, which may be subject to bias.
• The company's expectations and beliefs regarding these matters may not materialize.
• Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances.
• The company needs additional capital.

Future Outlook

The company is currently conducting a Phase 2 trial of Auxora in patients with Stage 2 or Stage 3 AKI and acute hypoxemic respiratory failure, which is expected to read out in 2025, and continuing to support the ongoing Phase 1/2 trial in pediatric patients with asparaginase-induced pancreatic toxicity with data expected in 2025.

Management Comments

• 'As illustrated by these data, the biological rationale for CRAC channel inhibition as a potential therapeutic mechanism for AKI is compelling,' said Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica.
• 'The post-hoc analysis from CARDEA is especially relevant given that the 62.7% relative reduction in mortality was observed in patients with both kidney failure and respiratory failure, which mirrors the intended patient population for our ongoing Phase 2 KOURAGE study.'

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing therapies for inflammatory and immunologic diseases, specifically those targeting acute kidney injury and respiratory failure. The results could position CalciMedica as a potential leader in CRAC channel inhibition therapies.

Comparison to Industry Standards

• It is difficult to compare the results directly to industry standards without knowing the specific patient populations and endpoints of other AKI trials.
• However, a 62.7% relative reduction in mortality is a clinically significant result that warrants further investigation.
• Companies like Akebia Therapeutics and Tricida are also developing therapies for kidney diseases, but their mechanisms of action differ from CalciMedica's CRAC channel inhibition approach.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of Auxora could provide a new treatment option for patients with AKI and respiratory failure.
• Positive results could improve employee morale and attract new talent.

Next Steps

• The company is currently conducting a Phase 2 trial (KOURAGE) in patients with AKI with associated acute hypoxemic respiratory failure with data expected in 2025.
• The company is continuing to support the ongoing Phase 1/2 trial (CRSPA) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025.

Key Dates